Prognostic factors for @entity1 with localized soft-tissue XXXX treated with conservation surgery and radiation therapy: an analysis of 1225 @entity1 .

@entity1 @entity82 @entity242 @entity5 @entity1352 @entity1822 @entity6011 @entity3 @entity980
BACKGROUND: Prognostic factors for @entity1 with soft-tissue @entity242 who are treated with conservative surgery and radiation are documented poorly. METHODS: The clinicopathologic features and disease outcome for 1225 @entity1 with @entity242 who were treated with conservative surgery and radiation were reviewed retrospectively. Actuarial univariate and multivariate statistical methods were used to determine significant prognostic factors for local control, metastatic recurrence, and disease specific survival. RESULTS: The median follow-up of surviving @entity1 was 9.5 years. The respective local control rates at 5 years, 10 years, and 15 years were 83%, 80%, and 79%. Factors predictive of local recurrence were positive or uncertain resection margins; @entity5 located in the head and neck and the deep trunk; presentation with local recurrence; @entity1 age > 64 years; malignant @entity82 , @entity6011 . or @entity242 histopathology; @entity5 measuring > 10 cm in greatest dimension; and high pathologic grade. Freedom from @entity3 at 5 years, 10 years, and 15 years was 71%, 68%, and 66%, respectively. Factors that were predictive of metastatic recurrence were high @entity5 grade; large @entity5 size (> 5 cm); and @entity1822 , @entity980 , @entity1352 , or @entity242 . The respective disease specific survival rates at 5 years, 10 years, and 15 years were 73%, 68%, and 65%. Adverse factors for disease specific survival were high @entity5 grade; large @entity5 size (> 5 cm); @entity5 located in the head and neck and deep trunk; @entity980 , @entity242 , or clear cell @entity242 ; @entity1 age > 64 years; and positive or uncertain resection margins. CONCLUSIONS: Soft-tissue @entity242 comprises a heterogeneous group of diseases. Prognostic factors for local recurrence, metastatic recurrence, lymph node recurrence, disease free survival, and disease specific survival are different, and optimal treatment strategies need to take this complexity into account.
